132 related articles for article (PubMed ID: 1793892)
1. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.
Peskar BA; Cawello W; Rogatti W; Rudofsky G
J Physiol Pharmacol; 1991 Sep; 42(3):327-31. PubMed ID: 1793892
[TBL] [Abstract][Full Text] [Related]
2. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
3. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis.
Leonhardt A; Krauss M; Gieler U; Schweer H; Happle R; Seyberth HW
Br J Dermatol; 1997 Mar; 136(3):337-40. PubMed ID: 9115911
[TBL] [Abstract][Full Text] [Related]
4. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V
Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905
[TBL] [Abstract][Full Text] [Related]
5. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.
Cawello W; Schweer H; Müller R; Bonn R; Seyberth HW
Eur J Clin Pharmacol; 1994; 46(3):275-7. PubMed ID: 8070511
[TBL] [Abstract][Full Text] [Related]
7. Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.
Cawello W; Leonhardt A; Schweer H; Seyberth HW; Bonn R; Lomeli AL
Br J Clin Pharmacol; 1995 Sep; 40(3):273-6. PubMed ID: 8527291
[TBL] [Abstract][Full Text] [Related]
8. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics.
Bothwell W; Verburg M; Wynalda M; Daniels EG; Fitzpatrick FA
J Pharmacol Exp Ther; 1982 Feb; 220(2):229-35. PubMed ID: 6948952
[TBL] [Abstract][Full Text] [Related]
9. Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.
Leonhardt A; Schweer H; Wolf D; Seyberth HW
Br J Clin Pharmacol; 1992 Mar; 33(3):323-5. PubMed ID: 1576056
[TBL] [Abstract][Full Text] [Related]
10. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of intravenously applied prostaglandin E1.
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome.
Cox JW; Andreadis NA; Bone RC; Maunder RJ; Pullen RH; Ursprung JJ; Vassar MJ
Am Rev Respir Dis; 1988 Jan; 137(1):5-12. PubMed ID: 3337471
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacologic concepts for clinical use of prostaglandin E1].
Schrör K
Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
[TBL] [Abstract][Full Text] [Related]
14. Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes.
Rady-Pentek P; Mueller R; Tang BK; Kalow W
Eur J Clin Pharmacol; 1997; 52(2):147-53. PubMed ID: 9174685
[TBL] [Abstract][Full Text] [Related]
15. Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.
Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA
Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):265-75. PubMed ID: 9653766
[TBL] [Abstract][Full Text] [Related]
16. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
Hyman AL; Kadowitz PJ
J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
[TBL] [Abstract][Full Text] [Related]
17. Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation.
Pallapies D; Peskar BA
Thromb Res; 1993 Aug; 71(3):217-25. PubMed ID: 8211888
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
[TBL] [Abstract][Full Text] [Related]
19. [Effects of intravenous prostaglandin E1 on bronchial histamine reactivity].
Wilkens JH; Wilkens H; Dickow M; Fabel H; Frölich JC
Pneumologie; 1990 Feb; 44 Suppl 1():446-8. PubMed ID: 2195528
[TBL] [Abstract][Full Text] [Related]
20. In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite.
Verburg M; Bothwell W; Daniels EG; Fitzpatrick FA
J Cardiovasc Pharmacol; 1982; 4(6):980-5. PubMed ID: 6185792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
